Robust financial growth for Kiniksa Pharmaceuticals in Q2 2025, including 52% YoY ARCALYST revenue growth & raised guidance.

Synopsys, Inc. (SNPS) is currently at $646.13, up $53.50 or 9.03% --Would be new all-time high (Based on available data back to Feb. 26, 1992) --Would be the first new record closing high since July 5 ...

There's plenty of reason to be optimistic about Synopsys' future; however, whether it could realistically make you a ...

China's tighter rare earth export controls are disrupting Apple's plan to expand manufacturing in India as Dixon Technologies ...

July 26, 2025 - The increasing expansion of cloud-based solutions is significantly driving the revenue growth of the Software ...

Shares of Synopsys Inc. SNPS slid 1.33% to $601.55 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.40% to 6,388.64 and ...

Stratasys benefits from strong fundamentals, a solid balance sheet, and growth drivers like mass production and onshoring.

We came across a bullish thesis on Cadence Design Systems, Inc. on Stock Analysis Compilation’s Substack. In this article, we ...